Arvinas Presents Preclinical Data for ARV-393 BCL6 Degrader at EHA 2025 Congress

Arvinas presented preclinical data for ARV-393, a PROTAC BCL6 degrader, at the European Hematology Association 2025 Congress. ARV-393 demonstrated significant single-agent activity in models of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type, and transformed follicular lymphoma. In combination with small molecule inhibitors, ARV-393 showed enhanced tumor growth inhibition and tumor regressions in models of aggressive diffuse large B-cell lymphoma.

Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company, presented preclinical data for ARV-393, an investigational PROteolysis TArgeting Chimera (PROTAC) B-cell lymphoma 6 protein (BCL6) degrader, at the European Hematology Association 2025 Congress in Milan, Italy. The data demonstrated significant single-agent activity in models of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type (AITL), and transformed follicular lymphoma. Additionally, ARV-393 showed enhanced tumor growth inhibition and tumor regressions in combination with small molecule inhibitors in models of aggressive diffuse large B-cell lymphoma (DLBCL).

The preclinical studies, presented in a poster titled "ARV-393, a PROTAC BCL6 Degrader, is Efficacious in Preclinical Models of Diffuse Large B-Cell Lymphoma, Nodal T-Follicular Helper Cell Lymphoma, and Transformed Follicular Lymphoma," highlighted the potential of ARV-393 in addressing unmet needs in B-cell lymphoma. The data indicated that ARV-393 significantly reduced tumor burden in peripheral blood, bone marrow, and spleen in a systemic patient-derived xenograft (PDX) model of AITL derived from a patient who relapsed post chemotherapy. The study also found that ARV-393 monotherapy resulted in robust (≥95%) tumor growth inhibition (TGI) in two PDX models of transformed follicular lymphoma (tFL). In combination with oral small molecule inhibitors (SMIs), ARV-393 demonstrated increased TGI in cell line-derived xenograft (CDX) models of high-grade B-cell lymphoma (HGBCL) and aggressive DLBCL compared to the respective monotherapy treatments. Tumor regressions were observed when ARV-393 was combined with tazemetostat, palbociclib, acalabrutinib, or venetoclax.

The results from these preclinical studies suggest the broad utility of ARV-393 across non-Hodgkin lymphoma subtypes with unmet need beyond DLBCL and provide a compelling rationale for considering combination strategies, including chemotherapy-free approaches. A Phase 1 study of ARV-393 is currently enrolling adult patients with relapsed/refractory non-Hodgkin lymphoma, including DLBCL and AITL (NCT06393738).

[1] https://www.globenewswire.com/news-release/2025/06/13/3098932/0/en/Arvinas-Presents-Preclinical-Data-for-PROTAC-BCL6-Degrader-ARV-393-at-the-European-Hematology-Association-2025-Congress.html
[2] https://finance.yahoo.com/quote/ARVN/press-releases/